The Infectious Diseases Data Observatory (IDDO) is a scientifically independent, multi-disciplinary coalition of the global infectious disease and emerging infections communities. It provides the methods, governance and infrastructure to translate data into evidence that improves outcomes for patients worldwide. Currently, IDDO has eight active areas of research with many more already in development or being scoped for feasibility.
Share data

If you work with clinical, laboratory or epidemiological data and want to share your research or access research data then you are welcome to sign up to the Observatory.

We have platforms for a range of diseases including emerging and neglected infections.

What is IDDO?

The Infectious Diseases Data Observatory (IDDO) is a researcher driven network which provides data platforms to capture, share and collaborate on infectious disease related data.

Using years of experience and extensive investment in data tools we provide platforms which are designed for effective data analysis and robust governance.

COVID-19

Explore our work on COVID-19

Research themes

IDDO enables research-driven responses to major challenges of infectious diseases through development and management of data sharing platforms.

Contributing data

Learn more about sharing your data through IDDO

Tools and resources

IDDO is committed to providing practical tools and services to support the collection of disease characterisation data and develop quality evidence on optimal treatment and response to emerging infections. 

Latest publications

Malaria Journal

Published: 26 Oct 2023

Author(s): Paul Sondo, Bérenger Kaboré, Toussaint Rouamba, Eulalie Compaoré, Yssimini Nadège Guillène Tibiri, Hyacinthe Abd-El Latif Faïçal Kaboré, Karim Derra, Marc Christian Tahita, Hamidou Ilboudo, Gauthier Tougri, Ismaïla Bouda, Tikan

Malaria Journal

Published: 10 Oct 2023

Author(s): Parinaz Mehdipour, Megha Rajasekhar, Saber Dini, Sophie Zaloumis, Tesfay Abreha, Ishag Adam, Ghulam Rahim Awab, J. Kevin Baird, Larissa W. Brasil, Cindy S. Chu, Liwang Cui, André Daher, Margarete do Socorro M Gomes, Lilia Gonzalez‑Ceron, Jimee Hwang, , Harin Karunajeewa, Marcus V. G. Lacerda, Simone Ladeia-Andrade, Toby Leslie, Benedikt Ley, Kartini Lidia, Alejandro Llanos-Cuentas, Rhea J. Longley, Wuelton Marcelo Monteiro, Dhelio B. Pereira, Komal Raj Rijal, Kavitha Saravu, , Inge Sutanto, Walter R. J. Taylor, Pham Vinh Thanh, Kamala Thriemer, José Luiz F. Vieira, Nicholas J. White, Lina M. Zuluaga-Idarraga, Philippe J. Guerin, Ric N. Price, Julie A. Simpson, Robert J. Commons on behalf of the WWARN Vivax Adherence Study Group

The Lancet Infectious Diseases

Published: 22 Sep 2023

Author(s): Megha Rajasekhar, Prof Julie A Simpson, Benedikt Ley, Peta Edler, Cindy S Chu, Tesfay Abreha, Ghulam R Awab, Prof J Kevin Baird, Germana Bancone, Bridget E Barber, Matthew J Grigg, Jimee Hwang, Harin Karunajeewa, Prof Marcus V G Lacerda, , Simone Ladeia-Andrade, Prof Alejandro Llanos-Cuentas, Prof Sasithon Pukrittayakamee, Komal R Rijal, Kavitha Saravu, Prof Inge Sutanto, Walter R J Taylor, Kamala Thriemer, James A Watson, Prof Philippe J Guerin, Prof Nicholas J White, Prof Ric N Price, Rob, on behalf of theWorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study Group